Alyeska Investment Group L.P. Raises Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Alyeska Investment Group L.P. raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 69.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 344,916 shares of the company's stock after buying an additional 141,732 shares during the quarter. Alyeska Investment Group L.P. owned about 0.66% of Janux Therapeutics worth $18,467,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of JANX. Russell Investments Group Ltd. lifted its stake in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares in the last quarter. Avanza Fonder AB purchased a new position in Janux Therapeutics during the fourth quarter worth approximately $139,000. Meeder Asset Management Inc. purchased a new stake in Janux Therapeutics in the 4th quarter valued at $159,000. Tower Research Capital LLC TRC increased its stake in shares of Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after acquiring an additional 3,436 shares during the last quarter. Finally, Chicago Capital LLC purchased a new position in shares of Janux Therapeutics during the 4th quarter worth $230,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Down 3.1 %

Shares of NASDAQ JANX traded down $0.81 during midday trading on Friday, hitting $25.56. The company had a trading volume of 742,298 shares, compared to its average volume of 856,417. The business has a 50-day simple moving average of $29.27 and a two-hundred day simple moving average of $41.67. Janux Therapeutics, Inc. has a twelve month low of $22.52 and a twelve month high of $71.71. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -21.85 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JANX. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $95.25.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 10,001 shares of company stock valued at $313,964. Insiders own 29.40% of the company's stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.